Prescient Therapeutics Ltd has released a press release.
Pipeline Collaboration for Next Generation Formulations
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Change of Registry Address: Automic P/L - Sydney Office
- Improved manufacturing route for PTX-100
- Appendix 4E and 2018 Annual Report
- PTX-200 AML Study Expanded
- June 2018 Appendix 4C - Quarterly
Later from Prescient Therapeutics
- September 2018 Appendix 4C - Quarterly
- Interim Durability Analysis of PTX-200 Breast Cancer Study
- December 2018 Appendix 4C - Quarterly
- Prescient Completes Equity Raising to Raise $9.1 Million
- Capital Raising Presentation - March 2019
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics